Drugmakers oppose expert “hot tubbing” in UK excessive pricing trial

Two drugmakers seeking to overturn nearly £70 million in excessive pricing penalties have urged the UK's Competition Appeal Tribunal not to compel concurrent expert evidence.

Unlock unlimited access to all Global Competition Review content